This may be attributable to the fairly low frequency of somatic mutations in VEGF-B observed in CRC (0.4%; www.cbioportal.org), but a bigger cohort is needed to identify any potential association with therapy. The gene discussed is VEGFB; the disease is colorectal carcinoma.